List of Stem Cells Companies in Japan - 12

A public biopharmaceutical company focused on developing novel cancer immunotherapies.

Celaid Therapeutics is a Japan-based biotechnology company, which has developed a platform technology to efficiently expand hematopoietic stem cells ex vivo without choosing its origins, including bone marrow, cord blood, or peripheral blood. By using the novel technology, we are developing a cell therapy product that brings HSC transplantation to the next level and helps patients with blood disorders. Our technology has many potential applications including gene/cell therapy that utilize gene editing on HSC. Our mission is to improve QOL of patients, their families, and HSC donors all over the world.

Cellusion is committed to pursuing a patient-centric approach at our cutting-edge research and development (R&D) for diseases where regenerative medicine technologies can create a unique value proposition. We expand the possibilities of people around the world both physically and mentally.

Dioseve Inc. Our revolutionary technology, DIO (Directly Induced Oocyte), is capable of producing an extremely large yield of fertilizable egg cells at a minimal cost.

iHeart Japan​ is an venture company developing regenerative medicine products.

Kidswell Bio Corporation (KWB), formerly known as Gene Techno Science, has been growing by leveraging our expertise in Biosimilar field in Japan. By 2024, four BS products were brought to market by our partner pharmaceutical companies as outcomes of co-developments between the companies and KWB. Besides, KWB has engaged in research and development for regenerative medicine with stem cells from human exfoliated deciduous teeth (SHED) since 2019, which targeted pediatric diseases, orphan disease and intractable disease with the aim of achieving comprehensive healthcare solutions for patients suffering from these diseases as well as for their families and caregivers. On the 1st of April 2024, the regenerative medicine business became independent as S-Quatre Corporation (SQ). KWB and SQ lead biosimilar business and regenerative medicine business　respectively, and grow together as two pillars of Kidswell Bio group. キッズウェル・バイオ株式会社(旧株式会社ジーンテクノサイエンス)はバイオシミラー医薬品事業により成長してきた。パートナー製薬企業との共同開発の結果、2024年までに4つのバイオシミラー製品を日本にて上市させている。一方で、2019年からは、乳歯由来歯髄幹細胞を用いた再生医療の研究開発に着手し、希少疾患、難病に加えて、小児疾患を重点的なターゲットと定め、患者様、及びそのご家族や介護者の方を含めた包括的なケアを目指した研究開発を行なってきた。KWBは2024年4月1日にこの再生医療事業を専門に行なう子会社である株式会社S-Quatreを設立し、現在はキッズウェル・バイオグループとしてバイオシミラーと再生医療の両事業を展開している。

Revolutionizing the Way We Treat Heart Failure Heart failure kills more people globally than any other ailments, yet there is no ultimate treatment for the condition. Our goal is to develop and commercialize an effective and reasonably-priced therapy for heart failure using a specific fibroblast cells we call “VCF”, that we obtain from the patient’s own heart. Our approach to heart failure therapy is quite different from other technologies in a sense that we do not want to replace what is “broken”, but rather we want to repair the damage by enhancing the cells’ own ability to heal.

OncoTherapy Science, Inc. provides pharmaceutical companies with yielded drug candidates by using outcomes obtained from joint research with universities and companies. These outcomes include oncogene information isolated by comprehensive analysis of genes specifically expressed in cancer cells and functional analysis information of proteins produced by oncogenes and other gene products. We have also been performing research and development business regarding medications.

This company is a spinout from Takeda Pharmaceuticals and Kyoto University, focusing on the development of induced pluripotent stem cell (iPSC) technology-based regenerative medicine.

Based on the discovery by our Founder, Professor Shimon Sakaguchi, we are developing stable, functional-induced Tregs that are antigen-specific (S/F-iTregs). Our S/F-iTregs address the limitations of earlier attempts to create therapeutic Tregs and competitive advantages over CAR-Treg approaches.

Rege Nephro is a clinical-stage biotech company developing cell therapy for chronic kidney disease (CKD) and small molecule for autosomal dominant polycystic kidney disease (ADPKD), and founded in 2019. There are 13 million patients with CKD in Japan, of which 340,000 are severe CKD patients forced to undergo artificial dialysis. The healthcare cost of dialysis is $12 billion, 4% of the total healthcare cost of Japan. However, there is still no curative treatment for CKD. Rege Nephro tries to treat patients suffering from CKD with cell therapy using nephron progenitor cells differentiated from iPS cells.

REPROCELL supports nearly the entire workflow of stem cell research and pre-clinical drug development. Our unique portfolio includes access to human tissues (BioServe) and human tissue testing (Biopta), in addition to stem cell culture media, reprogramming technologies, reagents, and iPSC-derived cell types (Stemgent). With our deep knowledge of stem cell biology, bioengineered (3D) tissue models (Alvetex) cell differentiation, and pharmacology, REPROCELL is a recognized leader in cutting-edge tools and services to accelerate regenerative medicine and drug development. The newly formed REPROCELL Medical business unit is developing a suite of reagents and services to meet the growing need for clinical-grade products and services that are appropriate for regenerative medicine. In addition, our labs offer diagnostic services for a variety of tests related to tissue compatibility and other biomarkers. And finally, REPROCELL also offers a GMP iPSC master cell bank manufacturing service. *** REPROCELL went public on the Japan JASDAQ in June 2013. Stemgent, BioServe and Reinnervate became parts of REPROCELL in 2014. Biopta was then acquired in 2015.